South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020 May 1; 318(5): H1084-H1090. doi: 10.1152/ajpheart.00217.2020.

Iaccarino G, Borghi C, Cicero AFG, Ferri C, Minuz P, Muiesan ML, et al. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Press Cardiovasc Prev. 2020 Apr 7. doi: 10.1007/s40292-020-00380-3.

Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and` the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020 Apr 15. pii: cvaa097. doi: 10.1093/cvr/cvaa097.

Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020 Apr 9; 14(4): 283-287. doi: 10.1016/j.dsx.2020.03.016.

Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020 Mar 25:HYPERTENSIONAHA12015082. doi: 10.1161/HYPERTENSIONAHA.120.15082.